98%
921
2 minutes
20
Background: Robotic surgery utilization has been increasing across surgical specialties; however, racial disparities in patient access to care and outcomes have been reported.
Objectives: In this study, we examined racial disparities in the utilization and outcomes of robotic bariatric surgery over an 8-year period.
Setting: Metabolic and Bariatric Surgery Accreditation Quality Improvement Program (MBSAQIP) centers of excellence across the United States.
Methods: The MBSAQIP database was used to identify adult patients who underwent robotic bariatric surgery between 2015 and 2022. Patients were stratified according to race and ethnicity into non-Hispanic White, non-Hispanic Black or African American (AA), Indigenous, Asian, and Hispanic patients. Multivariable analyses were used to assess predictors of robotic surgery use, odds of minor and major complications, prolonged length of stay (prolonged length of stay (pLOS): ≥3 days), readmissions, reoperations, and mortality within 30 days.
Results: Out of 1,288,359 patients included, robotic surgery was utilized in 196,314 patients (15.2%), with a mean age of 44 ± 12 years and 80.6% females. Rates of robotic surgery increased to 30% by 2022. Compared to White patients, Black/AA patients were more likely to undergo robotic surgery (adjusted odds ratio (aOR) = 1.22, 95% confidence interval (CI) = 1.21-1.24, P < .001). The safety of robotic bariatric surgery improved for both White and Black patients with decreased odds of major complications, readmissions, reoperations, and pLOS over the study period. However, Black/AA patients were more likely to experience minor and major complications, readmissions and have pLOS compared with White patients in 2022 (aOR:1.26, 95% CI:1.19-1.34, P < .001; aOR:1.22, 95% CI:1.06-1.41, P = .006; aOR:1.44, 95% CI:1.28-1.62, P < .001; aOR:2.26, 95% CI:2.06-2.47, P < .001, respectively).
Conclusion: The utilization of robotic bariatric surgery has increased significantly over the past 8 years with continued improvements in its safety profile. While Black/AA patients have improved access to robotic surgery, their clinical outcomes continue to be worse than those of White patients. Efforts to address racial disparities in bariatric surgery outcomes must remain a priority to achieve health equity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11820883 | PMC |
http://dx.doi.org/10.1016/j.soard.2024.09.002 | DOI Listing |
Diabetes Res Clin Pract
September 2025
Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan; School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan. Electronic address:
Obes Surg
September 2025
Department of Nephrology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Obes Surg
September 2025
Department of Medical and Surgical Sciences, Internal Medicine Unit, Columbus-Gemelli Hospital, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Obesity is a globally prevalent condition associated with elevated morbidity and mortality. Metabolic and bariatric surgery offers a definitive treatment for class III (BMI > 40) obesity, achieving substantial, enduring weight loss and improving metabolic health. Despite extensive research on the physical benefits, comparatively fewer reviews investigate the psychosocial and relational changes accompanying these procedures.
View Article and Find Full Text PDFObes Surg
September 2025
Department of Minimally Invasive Digestive Surgery, Antoine Béclère Hospital, AP-HP, 157 Rue de La Porte de Trivaux, 92141 Clamart, Clamart, France.
Background: Bariatric surgery (BS) is the most effective treatment for severe obesity, but a significant proportion of patients experience insufficient weight loss (IWL) or weight regain. Glucagon-like peptide-1 receptor agonists (arGLP-1) have emerged as a promising adjunctive therapy for managing these suboptimal outcomes. This study evaluates the efficacy and safety of arGLP-1 in patients with IWL or WR after BS.
View Article and Find Full Text PDFJ Arthroplasty
September 2025
Virginia Commonwealth University Health System, Department of Orthopaedic Surgery, 1200 E Broad St, Richmond, VA, 23298, USA.
Introduction: Obesity is an increasingly prevalent comorbidity that confers greater risks of postoperative complications following total joint arthroplasty, underscoring the need for viable preoperative weight loss. The objective of this study was to compare the risk of 90-day adverse events in patients undergoing total knee arthroplasty (TKA) following bariatric surgery versus treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA).
Methods: A retrospective review of a national research network from May 1, 2005, to February 12, 2025, identified patients undergoing TKA with bariatric surgery or GLP-1 RA prescriptions in the 18 months preceding their joint arthroplasty.